Terminal2 — Card #00: [Diagnosis Name]

S01 Everyone

What Is It

End-stage renal disease at end of life — dialysis as life support, the withdrawal decision, the uremic symptom burden, and what the hospice team needs to understand on day one.

ESRD Prevalence

~785,000

Americans currently receiving renal replacement therapy — approximately 560,000 on hemodialysis, 50,000 on peritoneal dialysis, and 230,000 living with a functioning kidney transplant. Incidence: ~125,000 new ESRD patients per year.^[1]

Dialysis Withdrawal / Year

25–30K

Voluntary dialysis withdrawal accounts for 15–25% of all ESRD deaths — the second leading cause of death in ESRD after cardiovascular disease. In patients over 75, withdrawal precedes 30–40% of deaths. Hospice referral rate after withdrawal: only 40–50%.^[2]

Racial Disparity

3.5×

Black Americans develop ESRD at 3.5× the rate of white Americans; Hispanic Americans at 1.5×; Indigenous Americans at 2×. Driven by higher rates of diabetic nephropathy, hypertensive nephrosclerosis, and structural determinants of health.^[3]

Medicare Cost

$50B+

Annual cost of ESRD care in the US exceeds $50 billion — approximately 7% of the total Medicare budget for approximately 1% of the Medicare population. ESRD is the most resource-intensive chronic disease per capita in American medicine.^[1]

End-stage renal disease is the final stage of chronic kidney disease — the point at which the kidneys can no longer sustain life without renal replacement therapy. ESRD (CKD Stage 5, eGFR <15 mL/min/1.73m²) means the patient's kidneys have lost virtually all filtration capacity. Without dialysis or transplantation, the accumulation of uremic toxins, fluid, and electrolytes — particularly potassium — produces death within days to weeks. Dialysis in ESRD is not a treatment in the way chemotherapy treats cancer; it is life support. The hemodialysis machine or peritoneal dialysis exchanges perform the function that the patient's kidneys cannot. When dialysis stops, the patient dies.^[4]

The decision to withdraw from dialysis is the central clinical event in ESRD hospice care. Unlike most hospice diagnoses where the disease progresses to death on its own timeline, ESRD death after withdrawal is a direct and foreseeable consequence of stopping the machine. The median survival after dialysis withdrawal is 7–14 days, with a range of 1–30+ days depending on residual renal function, comorbidities, nutritional status, and age. This makes ESRD post-withdrawal one of the most acutely time-limited hospice enrollments in all of medicine — the comfort plan must be complete before the patient leaves the withdrawal conversation.^[5]

The uremic symptom burden that develops after dialysis withdrawal is distinctive and requires specific management. As uremic toxins accumulate, patients experience pruritus (the most refractory and undertreated symptom in ESRD), nausea, fatigue, encephalopathy, and myoclonus. Volume overload produces pulmonary edema and respiratory distress. Hyperkalemia produces fatal cardiac arrhythmias. The hospice clinician who understands these specific physiological crises — and who has placed the right medications in the home before the last dialysis session — can ensure that the patient who made the most autonomous decision in all of end-of-life medicine experiences a death free of preventable suffering.^[6]

🧭 Clinical Framing

The key thing hospice teams must internalize: dialysis withdrawal is functionally equivalent to ventilator removal in a patient who is awake and making the decision. The patient who stops dialysis is not passively declining — they are sitting across a table, cognitively intact, choosing to stop the machine that is keeping them alive, knowing that in one to two weeks they will be dead. They have had years of three-times-weekly sessions to think about this. They have earned this decision. What the hospice clinician brings is not the decision itself — the patient already has that — but the clinical precision to ensure that what comes after the decision is as free of suffering as medicine can make it.^[7]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The first time you walk into the home of an ESRD patient who's decided to stop dialysis, you need to understand what you're walking into. This person is not confused. They are not depressed. They have spent years on that machine and they have decided they are done. Your job is not to evaluate the decision — your job is to make sure the next ten days are worthy of the courage it took to make it. Get the gabapentin, the mirtazapine, the fentanyl, and the written timeline into that home before the last session. Everything else is details."

— Waldo, NP · Terminal2

S02 Clinician

How It's Diagnosed

GFR-based CKD staging, key laboratory values for hospice, and what to look for in records. Most ESRD patients arrive with years of documented kidney disease — this section helps you read it.

GFR-Based CKD Staging

Glomerular filtration rate (GFR) is the primary measure of kidney function. Estimated GFR (eGFR) is calculated from serum creatinine using the CKD-EPI equation.^[8]

Stage 1: eGFR ≥90 mL/min/1.73m² — kidney damage with normal function
Stage 2: eGFR 60–89 — mildly reduced
Stage 3a: eGFR 45–59 — mildly to moderately reduced
Stage 3b: eGFR 30–44 — moderately to severely reduced
Stage 4: eGFR 15–29 — severely reduced; transplant evaluation and dialysis planning begin
Stage 5: eGFR <15 — kidney failure; ESRD is Stage 5 requiring renal replacement therapy^[9]

The eGFR at hospice enrollment and its 3–6 month trend document the degree of residual renal function — this determines post-withdrawal survival duration. The patient with residual eGFR of 5–8 will survive longer after withdrawal than the anuric patient.^[10]

Key Laboratory Values for Hospice

BUN (Blood Urea Nitrogen): Normal <20 mg/dL. Uremic symptoms typically appear above 100 mg/dL. BUN >150–200 mg/dL is associated with significant encephalopathy. The rate of BUN rise after withdrawal predicts symptom trajectory.^[11]
Serum Creatinine: Less useful as an absolute value after withdrawal — does not accumulate as rapidly as uremic toxins. The trend is more informative than the absolute value.
Serum Potassium: Normal 3.5–5.0 mEq/L. >6.0 mEq/L produces cardiac arrhythmia risk. >7.0 mEq/L produces lethal arrhythmia risk (peaked T waves, widened QRS, sine wave pattern). In anuric patients after withdrawal, potassium rises ~0.5–1.0 mEq/L per day.^[12]
Serum Bicarbonate: Normal 22–28 mEq/L. Metabolic acidosis (<18 mEq/L) worsens uremic symptoms, increases respiratory compensation (Kussmaul breathing), and contributes to nausea.^[13]
Phosphorus: Elevated phosphorus contributes to pruritus intensity and soft tissue calcification. Monitor as a pruritus driver in ESRD.^[14]
Calcium: Hypocalcemia from loss of renal vitamin D activation; hyperphosphatemia shifts calcium balance. Can produce tetany and neuromuscular irritability.

💡 For Families

Your loved one's kidneys have gradually lost the ability to filter waste products from the blood. By the time someone reaches end-stage kidney disease, their kidneys are working at less than 15% of normal capacity — which is why dialysis was needed. All of the diagnostic workup was completed long before hospice enrollment. The medical team already knows the exact stage and trajectory. The focus now is entirely on comfort and quality of the time that remains.^[8]

S03 Everyone

Causes & Risk Factors

Why ESRD develops, the diseases that drive it, and the health disparities that place the burden disproportionately on communities of color.

Primary Causes of ESRD

Diabetic nephropathy (~44%): The leading cause of ESRD in the US. Kimmelstiel-Wilson nodular glomerulosclerosis destroys glomerular filtration over years of uncontrolled hyperglycemia. ESRD patients with diabetic nephropathy almost invariably have concurrent peripheral neuropathy, autonomic neuropathy, retinopathy, and cardiovascular disease. The neuropathic pain persists after dialysis withdrawal and must be managed alongside uremic symptoms.^[15]
Hypertensive nephrosclerosis (~28%): The second leading cause. Decades of uncontrolled hypertension produce arteriolar nephrosclerosis, progressive glomerular ischemia, and tubular atrophy. Patients typically have concurrent LVH, heart failure, and peripheral vascular disease.^[15]
Glomerulonephritis (~7%): Various primary and secondary glomerular diseases including IgA nephropathy, lupus nephritis, and FSGS. Younger onset; may have been on immunosuppressive therapy.^[16]
Polycystic kidney disease (PKD) (~3%): Autosomal dominant; ESRD typically in 50s–60s. PKD patients also have hepatic cysts, intracranial aneurysm risk, and chronic flank pain from cyst hemorrhage and infection. Younger ESRD diagnosis than diabetes or hypertension patients.^[16]

Health Disparities & Non-Modifiable Factors

Black Americans: 3.5× rate of ESRD compared to white Americans. Driven by higher prevalence of diabetes and hypertension, APOL1 genetic variants (renal risk alleles), and structural factors including reduced access to early nephrology care.^[3]
Hispanic Americans: 1.5× rate. Higher diabetes prevalence, barriers to healthcare access, and lower transplant rates.^[17]
Indigenous Americans: 2× rate. Disproportionate diabetes burden, geographic barriers to dialysis centers, and historical underfunding of Indian Health Service renal programs.^[17]
Structural determinants: Food insecurity (access to renal-appropriate diet), poverty (medication non-adherence), lack of primary care (late nephrology referral), dialysis facility proximity, and transplant access disparities. Black patients are less likely to be referred for transplant, less likely to complete transplant evaluation, and more likely to remain on dialysis long-term.^[18]
Age: ESRD incidence peaks in the 65–74 age group. The elderly patient with multiple comorbidities has the highest burden but also the population most likely to benefit from conservative kidney management.^[1]

❤️ For Families: "Why Did This Happen?"

Kidney failure is most often caused by diabetes or high blood pressure — conditions that develop over many years, often decades. Your loved one did not cause this by doing something wrong. Kidney disease is frequently silent until it is very advanced. Even with the best medical care, some kidneys reach the point where they can no longer function. The years of dialysis your loved one endured were years of fighting to stay alive. That fight is not a failure — it is a testament to their strength. The decision to stop dialysis when it is no longer adding quality to life is an act of wisdom and courage, not of giving up.^[15]

⚕ Clinician Note: Structural Racism & the CKD-EPI 2021 Equation

The historic use of a race-based correction factor in the GFR equation (adding ~16% to eGFR for Black patients) systematically overestimated kidney function in Black Americans, delaying CKD diagnosis, nephrology referral, and transplant evaluation. The CKD-EPI 2021 race-free equation eliminated this correction and is now the recommended standard.^[19] Social determinants of health — not genetics alone — drive the disproportionate ESRD burden in communities of color. Food deserts produce diets high in sodium and processed sugar; lack of primary care access delays diagnosis; historical medical mistrust (rooted in events like the Tuskegee study) reduces engagement with advance care planning and dialysis withdrawal conversations.^[20] The hospice clinician must be aware of these dynamics, particularly when discussing withdrawal with Black patients and families where trust in the medical system may be lower.

S04 Clinician Everyone

Treatments & Procedures

Dialysis withdrawal as the central clinical process, uremic symptom management protocols, opioid safety in ESRD, and conservative kidney management. The most critical section for ESRD hospice care.

Dialysis withdrawal is THE central clinical process in ESRD hospice. Unlike most hospice diagnoses where disease progression drives the terminal course, in ESRD the patient makes an active decision to stop the intervention that is sustaining life. The hospice clinician's role is to ensure that every anticipated symptom has a pre-positioned management plan, that the family has a written day-by-day timeline, and that every medication in the home is dosed correctly for absent renal function. The withdrawal conversation, the last dialysis session, and the 7–14 day post-withdrawal trajectory require clinical precision that must be prepared before the patient's last session — not after.^[5]

The Withdrawal Conversation

The decision to stop dialysis is the patient's autonomous right. The clinician's responsibility is ensuring the decision is informed:^[21]

Expected symptoms: Pruritus worsening, nausea, fatigue, progressive encephalopathy, myoclonus, volume overload with dyspnea
Timeline: Median 7–14 days depending on residual function; anuric patients progress faster
Comfort plan: Every anticipated symptom has a specific medication and protocol ready before the last session
Option to resume: Must be explicitly stated — the patient can restart dialysis if they change their mind, though this option is rarely exercised. Once significant uremic encephalopathy develops, the patient loses capacity to request resumption.^[22]
Documentation requirements: Patient's stated reasons for withdrawal; understanding of timeline and symptoms; expressed wishes for symptom management; DNR/DNI status; hospitalization preferences; healthcare proxy identification and their understanding of the plan^[23]

Dialysis Modality Considerations

HD withdrawal — the sharper trajectory: Hemodialysis provides the most efficient toxin and fluid clearance. When HD stops, uremic toxins and fluid accumulate rapidly. The HD patient who stops dialysis will typically develop significant uremic symptoms within 3–5 days and progress to death within 7–14 days. The last HD session is a defined clinical clock.^[5]
PD withdrawal — slower trajectory: Peritoneal dialysis is less efficient than HD, and residual renal clearance often continues longer. The PD patient who stops exchanges will have a more gradual rise in uremic toxins. Survival after PD withdrawal may extend to 2–3 weeks or longer in patients with significant residual function.^[24]
The last session: Some patients want a ceremony or ritual for the last dialysis session; some want it to be unremarkable. Honor the patient's preference. The hospice team should plan to see the patient within 24 hours of the last session to verify that all comfort medications are in the home and the family has the written symptom timeline.^[25]

🚨 MORPHINE IS CONTRAINDICATED IN ESRD

Fentanyl is the opioid of choice in ESRD — never morphine. Morphine is metabolized to morphine-6-glucuronide (M6G), an active metabolite that is renally cleared. In ESRD, M6G accumulates to toxic levels, producing excessive sedation, myoclonus, seizures, and respiratory depression at doses that are safe in patients with normal renal function. This is not a dosing preference — it is a medication safety contraindication. Fentanyl is metabolized hepatically to inactive norfentanyl with no renally cleared active metabolites. Document the morphine contraindication in the medication safety section, the allergy list (as "MORPHINE — CONTRAINDICATED IN ESRD: M6G accumulation causes seizures and respiratory depression"), and every covering clinician handoff.^[26]^[27]

Uremic Pruritus Management — Complete Protocol

Gabapentin 100 mg PO QD (ESRD dose) | Mirtazapine 7.5 mg PO QHS | Menthol 1% cream PRN | Emollients BID

Uremic pruritus affects 40–50% of dialysis-dependent patients and nearly all post-withdrawal patients. It is mechanistically distinct from allergic or hepatic itch — driven by uremic toxin accumulation, kappa-opioid receptor imbalance, and central sensitization. Antihistamines (diphenhydramine, hydroxyzine) are ineffective and should not be in the plan.^[28]

Gabapentin 100 mg PO once daily (ESRD dose — NOT 300 mg): First-line pharmacological treatment. Normal dosing is 300–1200 mg TID; in ESRD with absent clearance, the drug accumulates significantly. Start 100 mg QD, titrate every 3 days to 100 mg TID maximum. Monitor for sedation — uremic encephalopathy compounds gabapentin CNS depression.^[29]
Mirtazapine 7.5 mg PO at bedtime: Triple-indication agent — addresses pruritus (5-HT2/5-HT3 antagonism), nausea (5-HT3 antagonism), and insomnia simultaneously. The 7.5 mg dose is more sedating than 15 mg due to preferential H1 histamine receptor occupancy at low dose.^[30]
Menthol 1% cream PRN: Topical cooling via TRPM8 receptor activation. No systemic absorption, no renal clearance concern. Apply to pruritic areas as needed for immediate relief between gabapentin doses.^[31]
Emollients (Eucerin, Cetaphil, or equivalent) BID: Skin barrier dysfunction in ESRD contributes to pruritus severity. Apply after bathing while skin is slightly damp. The simplest and most evidence-supported topical intervention.^[32]
Difelikefalin (Korsuva) if available: Kappa-opioid receptor agonist, FDA-approved for CKD-associated pruritus on dialysis. IV formulation given at end of dialysis session; availability in hospice settings is limited. If the patient was receiving difelikefalin during dialysis, it will no longer be available after withdrawal.^[33]

Volume Overload Management

Fentanyl 12.5–25 mcg SQ q4h PRN dyspnea | Furosemide 80–200 mg IV/PO trial | Metolazone 5 mg PO adjunct

After dialysis withdrawal, the anuric patient accumulates approximately 1–2 liters of fluid per day from oral intake and metabolic water production. Pulmonary edema and respiratory distress are the primary sources of acute suffering in post-withdrawal days 3–10.^[34]

Fentanyl for dyspnea: The primary comfort intervention. Opioid-naive: fentanyl 12.5–25 mcg SQ q4h with PRN doses. Titrate to dyspnea relief. Transdermal fentanyl patch 12–25 mcg/h for ongoing management.^[27]
Furosemide trial: In patients with any residual urine output (even 100–200 mL/day), high-dose furosemide (80–200 mg IV or PO) may produce enough diuresis to reduce volume overload symptoms. If no urine response after two doses, discontinue — furosemide in an anuric patient is futile.^[35]
Metolazone 5 mg PO: Thiazide-like diuretic that works synergistically with furosemide in patients with residual nephron function. Give 30 minutes before furosemide.^[35]
Head-of-bed elevation: 30–45 degrees reduces orthopnea and pulmonary congestion. Simple, immediate, and effective.
Fluid restriction counseling: Gentle education about reducing oral fluid intake if the patient is able and willing — but comfort and thirst management take priority over strict fluid restriction in a dying patient.

Hyperkalemia in Comfort-Focused Care

Sodium polystyrene sulfonate (Kayexalate) 15–30 g PO/PR: Potassium-binding resin; may reduce serum K+ by 0.5–1.0 mEq/L per dose. Consider if potassium >6.5 mEq/L and the patient is symptomatic. Constipation risk.^[36]
Dietary restriction vs. comfort: In the actively dying patient, restricting potassium-containing foods (bananas, oranges, tomatoes) may reduce quality of remaining time. If the patient wants the food, prioritize comfort over electrolyte management.^[37]
ECG monitoring decisions: In the comfort-focused post-withdrawal patient, ECG monitoring for hyperkalemia should be guided by goals of care. Continuous cardiac monitoring is not consistent with a comfort focus. If the patient develops palpitations or arrhythmia symptoms, treat with benzodiazepine for distress rather than aggressive K+ lowering.^[12]
Clinical note: Fatal hyperkalemia (K+ >7.0 mEq/L) typically develops at day 4–14 in an anuric patient on an unrestricted diet. The cardiac arrhythmia from lethal hyperkalemia is often rapid and painless — it may be the mechanism of death rather than a symptom to treat.

Uremic Encephalopathy & Myoclonus

The natural sedation of uremia: As BUN rises above 150–200 mg/dL, progressive encephalopathy produces confusion, somnolence, and ultimately coma. This uremic sedation is a natural anesthetic process — the patient who becomes unresponsive from uremia is not suffering from the encephalopathy itself. Families must be prepared for this progression.^[38]
Haloperidol 0.5–1 mg PO/SQ q6h PRN: For agitation associated with uremic encephalopathy. Low-dose haloperidol is preferred over benzodiazepines for delirium management. Haloperidol does not require significant renal dose adjustment.^[39]
Midazolam 1–2 mg SQ/IV q4h PRN: For uremic myoclonus — the involuntary jerking movements that develop in advanced uremia. Myoclonus is not seizure activity but is distressing to families. Midazolam addresses both the myoclonus and associated anxiety. Hepatically metabolized.^[40]
Gabapentin caution: Gabapentin being given for pruritus may worsen encephalopathy as uremia deepens. Reduce or discontinue gabapentin if sedation becomes excessive.

Nausea Management in ESRD

Ondansetron 4 mg PO/SL/IV q6h PRN: First-line antiemetic. 5-HT3 antagonist. No significant renal dose adjustment. Effective for uremic nausea.^[41]
Haloperidol 0.5–1 mg PO/SQ q8h: Dual-use for nausea and agitation. D2 receptor antagonism addresses the central component of uremic nausea. Low dose is effective.^[39]
Mirtazapine 7.5 mg QHS: Already prescribed for pruritus; its 5-HT3 antagonism provides additional nausea coverage at bedtime. The triple-indication benefit (pruritus + nausea + sleep) makes mirtazapine one of the most efficient medications in the ESRD comfort regimen.^[30]
NOT metoclopramide: Metoclopramide is renally cleared with significantly increased risk of extrapyramidal symptoms (EPS) and tardive dyskinesia in ESRD. Avoid in ESRD patients.^[42]

Conservative Kidney Management (CKM)

For patients with advanced CKD Stage 5 who choose not to initiate dialysis — an evidence-based alternative pathway.^[43]

Patient population: Elderly patients (>75) with high comorbidity burden, especially those with severe heart failure, advanced dementia, or poor functional status. In this population, CKM outcomes are equivalent to or better than dialysis in multiple observational studies.^[44]
Median survival: From eGFR <10 mL/min, CKM patients survive 6–23 months depending on age and comorbidity.^[45]
Trajectory: More gradual than post-dialysis withdrawal. Uremic symptoms develop slowly; pruritus, nausea, and fatigue increase over weeks to months. The CKM patient has a longer window for comfort management but requires earlier palliative integration.
Hospice enrollment: CKM patients are eligible for hospice when prognosis is ≤6 months. The trajectory is more similar to advanced heart failure than to acute post-withdrawal ESRD.^[46]

S05 Clinician

When Therapy Makes Sense

Comfort interventions that should START immediately at hospice enrollment — not after the withdrawal, not at the second visit, not when symptoms worsen. Day one.

In ESRD hospice, the comfort interventions that matter most must begin at enrollment — not after dialysis withdrawal. Uremic pruritus is present in 40–50% of dialysis-dependent ESRD patients and in nearly all post-withdrawal patients. The patient who has been scratching for months while on dialysis has been undertreated. The hospice clinician who arrives and prescribes gabapentin 100 mg daily and mirtazapine 7.5 mg at bedtime may provide more relief from pruritus in one week than the patient received in the preceding year of dialysis. The post-withdrawal symptom timeline document, the opioid selection, the volume overload plan, and the advance directive addressing emergency dialysis — all of these must be complete before the last session.^[28]^[47]

01

Pruritus management from day one: Start gabapentin 100 mg PO at bedtime (ESRD dose) AND mirtazapine 7.5 mg PO at bedtime at the enrollment visit — regardless of whether dialysis withdrawal has been decided. Leave both medications in the home. Add menthol 1% cream and an emollient. The patient who has been scratching for years and who receives effective pruritus treatment for the first time at hospice enrollment may have their quality of remaining life transformed by a $40 pharmacy order. Do NOT start with antihistamines — they do not work for uremic pruritus.^[29]^[30]
02

Opioid selection — fentanyl, NOT morphine: Document the ESRD-specific opioid contraindication for morphine in the medication safety section of the care plan. Ensure all covering clinicians understand: fentanyl is the opioid in ESRD. The opioid-naive ESRD patient with dyspnea from volume overload receives fentanyl 12.5–25 mcg SQ q4h with PRN. For chronic pain or ongoing dyspnea, transdermal fentanyl patch 12–25 mcg/h q72h.^[26]^[27]
03

Volume overload comfort management protocol: Fentanyl for dyspnea; furosemide trial for residual diuretic effect (80–200 mg — if no response after two doses, discontinue); metolazone 5 mg adjunct; head-of-bed elevation to 30–45 degrees. The post-withdrawal patient who develops acute pulmonary edema requires fentanyl at the bedside immediately — this medication must be in the home before the last dialysis session.^[34]^[35]
04

Post-withdrawal symptom timeline document: Must be written, reviewed with the family point by point, and physically left in the home BEFORE the last dialysis session. Days 1–3: fatigue, pruritus worsening, nausea. Days 3–7: volume overload, rising BUN, early encephalopathy. Days 7–14: progressive encephalopathy, myoclonus, uremic coma. The family who has the written timeline reads day 5 and says "the nurse told us this would happen." The family without the written timeline calls 911.^[47]
05

Dialysis catheter removal planning: The tunneled central venous catheter should be assessed for removal after withdrawal. Its continued presence adds infection risk and wound care burden without clinical benefit. Coordinate with interventional radiology or the vascular access team. Some patients want the catheter removed immediately (closure); others are not bothered by it. AV fistulas do not require intervention and will naturally clot over time.^[48]
06

CKM pathway for patients not on dialysis: Patients with advanced CKD Stage 5 who choose conservative kidney management (not starting dialysis) require the same symptom management as post-withdrawal patients but on a longer timeline. Pruritus, nausea, and fatigue management begin immediately. Hospice enrollment when prognosis ≤6 months. The CKM patient over 75 with high comorbidity burden may have outcomes equivalent to dialysis.^[43]^[45]
07

Advance directive must specifically address emergency dialysis: After the documented withdrawal decision, the advance directive must explicitly state that emergency dialysis is not consistent with the patient's goals. Emergency dialysis initiated during a volume overload crisis or hyperkalemia event by responders or family members does not reverse the terminal trajectory — it delays death while the patient regains consciousness and must make the withdrawal decision again. This is among the most distressing preventable events in ESRD hospice care.^[23]^[22]

S06 Clinician

When It Doesn't

Interventions that cause harm in ESRD hospice. Every item on this list has been prescribed in the field by clinicians who did not know the ESRD-specific contraindication.

ESRD produces the most pharmacokinetically dangerous prescribing environment in hospice medicine. The absent kidneys cannot excrete renally cleared medications and their metabolites, meaning that drugs and active metabolites accumulate to toxic levels at doses that are safe in patients with normal renal function. Every item below has caused preventable harm in ESRD patients — not from negligence, but from failure to recognize the ESRD-specific contraindication. The medication reconciliation at hospice enrollment is a patient safety event, not a routine administrative task.^[26]^[49]

01

Morphine: Morphine-6-glucuronide (M6G) accumulation in ESRD produces excessive sedation, myoclonus, seizures, and respiratory depression at standard hospice doses. This is a medication safety emergency — not a prescribing preference. If morphine has been prescribed by a covering clinician without knowledge of the ESRD-specific contraindication, contact the prescriber immediately and substitute fentanyl. Fentanyl is hepatically metabolized to inactive norfentanyl; no renally cleared active metabolites.^[26]^[27]
02

NSAIDs (including ketorolac): NSAIDs inhibit renal prostaglandins that maintain residual renal blood flow. In ESRD, they can completely eliminate residual renal function, worsen volume overload through sodium and water retention, and worsen hyperkalemia. They add nothing to comfort that cannot be provided by acetaminophen and fentanyl. Ketorolac is never appropriate in ESRD regardless of the pain indication.^[49]
03

Emergency dialysis after documented withdrawal: Once the patient has made an informed and documented decision to withdraw, emergency dialysis during hospice enrollment requires the patient's explicit re-consent. Emergency dialysis initiated by well-meaning family members or responders during a volume overload crisis or hyperkalemia event does not reverse the terminal trajectory — it delays death by days while the patient regains consciousness and must make the withdrawal decision again. The advance directive must specifically state that emergency dialysis is not consistent with the patient's goals after the documented withdrawal decision.^[22]^[23]
04

High-dose corticosteroids without clear palliative indication: Dexamethasone can provide brief symptomatic benefit for nausea and appetite, but does not reverse uremic encephalopathy and adds hyperglycemia in diabetic patients (44% of ESRD population). High-dose steroids without a specific symptom target worsen fluid retention and delirium.^[50]
05

Aggressive fluid resuscitation in volume-overloaded post-withdrawal patient: The hypotensive post-withdrawal patient is volume-overloaded, not volume-depleted. IV fluid boluses in this context worsen pulmonary edema and respiratory distress. Hypotension in the post-withdrawal patient is from cardiac dysfunction and uremic cardiomyopathy — not from dehydration. Manage with positioning and comfort measures, not fluids.^[34]
06

Antihistamines for uremic pruritus: Diphenhydramine, hydroxyzine, and cetirizine do not work for uremic pruritus. Uremic itch is not histamine-mediated — it is driven by uremic toxin accumulation, kappa-opioid receptor imbalance, and central sensitization. Antihistamines add sedation and anticholinergic burden without addressing the mechanism. Gabapentin and mirtazapine are the evidence-based treatments. The antihistamine order for uremic pruritus should be questioned at every enrollment.^[28]^[29]
07

Continuing antihypertensives, statins, phosphate binders in actively dying patient: Medication reconciliation at enrollment must identify medications that no longer serve a comfort purpose. Antihypertensives that were prescribed for renal protection are no longer appropriate — discontinue unless needed for symptom management (e.g., clonidine for sympathetic hyperactivity). Statins provide no comfort benefit. Phosphate binders (sevelamer, calcium acetate) may be discontinued if the pill burden contributes to nausea. Every medication in the dying patient must earn its place by addressing a comfort symptom.^[47]^[50]

📋 Medication Reconciliation at Enrollment

The ESRD patient arriving at hospice enrollment is typically taking 12–18 medications. The medication reconciliation is not a routine administrative task — it is a patient safety event. Priorities: (1) Identify and remove morphine if present — substitute fentanyl. (2) Remove NSAIDs. (3) Remove metoclopramide — substitute ondansetron or haloperidol. (4) Assess all remaining medications for renal dose adjustment. (5) Discontinue medications without a comfort indication: statins, phosphate binders, erythropoiesis-stimulating agents, and antihypertensives not being used for symptom management. (6) Ensure gabapentin is at the ESRD dose (100 mg QD, not 300 mg TID). Complete this reconciliation at the first visit — not the second.^[49]

S07 Everyone

Out-of-the-Box Approaches

Evidence-graded integrative and pharmacological approaches for ESRD symptom management. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Gabapentin for Uremic Pruritus

Grade A

ESRD dose: 100 mg PO once daily; titrate q3d to 100 mg TID max (NOT standard 300–1200 mg TID)

Multiple RCTs have demonstrated significant reduction in uremic pruritus severity with gabapentin versus placebo in dialysis-dependent CKD patients. The systematic review by Rayner et al. and the meta-analysis by Naini et al. confirm Grade A evidence for this indication.^[29]^[51]

Mechanism: Reduction of central sensitization — uremic toxin-mediated sensitization of spinal dorsal horn neurons that amplifies itch signaling — plus a modulatory effect on kappa-opioid receptor pathways^[52]
Critical ESRD dosing: Normal renal function dosing (300–1200 mg TID) will produce toxicity in ESRD. With absent renal clearance, gabapentin accumulates significantly. Start 100 mg once daily; titrate every 3 days. Maximum 100 mg TID in post-withdrawal patients.
Monitoring: Sedation is the dose-limiting side effect. Uremic encephalopathy will compound gabapentin CNS depression — reduce or stop gabapentin as encephalopathy deepens in the post-withdrawal trajectory.^[29]
Combination: Gabapentin for pruritus plus mirtazapine at bedtime for pruritus and sleep addresses the two most common nocturnal symptom burdens in post-withdrawal ESRD simultaneously.

Mirtazapine — Triple-Indication Comfort Agent

Grade B

7.5–15 mg PO at bedtime (QHS)

Mirtazapine at 7.5–15 mg QHS addresses three simultaneous comfort problems in post-withdrawal ESRD through three distinct pharmacological mechanisms, supported by case series, small trials, and strong mechanistic rationale.^[30]

Pruritus: 5-HT2 and 5-HT3 receptor antagonism reduces the serotonergic component of uremic itch. Evidence from case series and small trials in uremic and cholestatic pruritus supports efficacy.^[53]
Nausea: 5-HT3 receptor antagonism — the same mechanism as ondansetron. Mirtazapine effectively manages uremic nausea and provides overnight antiemetic coverage that ondansetron does not.
Sleep: H1 histamine receptor antagonism at 7.5 mg produces sedation that addresses the insomnia of uremic pruritus and nocturnal itch-scratch cycling. The 7.5 mg dose is paradoxically more sedating than 15 mg due to preferential H1 receptor binding at low dose.
Pharmacokinetics: Hepatically metabolized. No significant dose adjustment for ESRD. Safe to combine with gabapentin.

Difelikefalin (Korsuva)

Grade A

0.5 mcg/kg IV at end of dialysis session (per KALM trial protocol)

Difelikefalin is a peripherally selective kappa-opioid receptor agonist, FDA-approved for the treatment of moderate-to-severe CKD-associated pruritus (CKD-aP) in adults undergoing hemodialysis.^[33]

KALM-1 trial (Fishbane et al. 2020, NEJM): Difelikefalin 0.5 mcg/kg IV at the end of each dialysis session significantly reduced worst itch intensity versus placebo at 12 weeks (primary endpoint met). Clinically meaningful reduction in pruritus severity.^[54]
KALM-2 trial (Topf et al. 2021): Confirmatory Phase 3 trial with consistent results. Both trials demonstrated significant improvement in itch-related quality of life measures.^[55]
Mechanism: Peripheral kappa-opioid receptor agonism restores the endogenous mu/kappa opioid balance that is disrupted in uremia. Does not cross blood-brain barrier; no euphoria or CNS opioid effects.
Hospice limitation: Currently available as IV formulation administered at the end of dialysis. Not available after dialysis withdrawal. If the patient was receiving difelikefalin during dialysis, transition to gabapentin + mirtazapine for post-withdrawal pruritus management.

Menthol 1% Cream for Pruritus

Grade B

Apply topically to pruritic areas PRN — available OTC in menthol-containing moisturizers

Menthol produces a cooling sensation through activation of TRPM8 (transient receptor potential melastatin 8) receptors in cutaneous sensory neurons, providing immediate but temporary relief from itch.^[31]

Mechanism: TRPM8 activation produces a competing sensory signal (cool) that overrides the itch signal at the spinal cord level. No systemic absorption at 1% concentration. No renal clearance concern. No drug interactions.
Clinical use: Provides immediate relief between gabapentin doses. Particularly useful for nocturnal itch exacerbations and localized pruritus. Can be applied as frequently as needed.
Evidence: Multiple small trials and clinical experience support efficacy as an adjunct. Not sufficient as monotherapy for severe uremic pruritus but valuable as part of the multimodal pruritus protocol.^[56]
Availability: OTC in Sarna lotion, menthol-containing Eucerin formulations, and compounding pharmacy preparations. Inexpensive and immediately available.

Nalfurafine

Grade B

2.5–5 mcg PO once daily (Japanese approved dosing)

Nalfurafine is a centrally acting kappa-opioid receptor agonist approved in Japan since 2009 for the treatment of uremic pruritus in hemodialysis patients. Not approved in the United States or Europe.^[57]

Mechanism: Unlike difelikefalin (peripheral kappa agonist), nalfurafine crosses the blood-brain barrier and acts on central kappa-opioid receptors. This dual central and peripheral action may explain its efficacy but also produces more CNS side effects (somnolence, insomnia).
Evidence: Multiple RCTs in Japanese hemodialysis populations demonstrated significant reduction in pruritus severity (Kumagai et al.). Post-marketing surveillance data from >15,000 patients support safety and efficacy.^[58]
Clinical relevance: Not available in US hospice settings. Included for completeness and because it validates the kappa-opioid mechanism as a therapeutic target in uremic pruritus.

Omega-3 Fatty Acids

Grade C

Fish oil 1–3 g PO daily (EPA/DHA combined)

Omega-3 polyunsaturated fatty acids have anti-inflammatory properties that may reduce the inflammatory component of uremic pruritus. Limited evidence from small trials in hemodialysis patients.^[59]

Mechanism: EPA and DHA reduce pro-inflammatory cytokines (IL-6, TNF-α) and prostaglandins that contribute to uremic itch. May also improve skin barrier function through incorporation into cell membranes.
Evidence: Small RCTs (Pakfetrat et al.) showed modest improvement in pruritus scores versus placebo. Effect size is less than gabapentin. Adjunctive role only.^[60]
Safety in ESRD: Generally well tolerated. Fish oil can increase bleeding time — relevant if the patient is on anticoagulation. GI side effects (fishy aftertaste, nausea) may worsen uremic nausea.
Clinical role: Reasonable adjunct for patients who tolerate it. Not a substitute for gabapentin or mirtazapine. May be appropriate for the CKM patient with a longer pruritus trajectory.

Capsaicin 0.025% Cream

Grade C

Apply topically to localized pruritic areas QID for 4–6 weeks (requires consistent use for efficacy)

Capsaicin desensitizes TRPV1 (transient receptor potential vanilloid 1) receptors in cutaneous C-fibers, depleting substance P and reducing itch signal transmission.^[61]

Mechanism: Initial TRPV1 activation produces burning and stinging (which limits tolerability), followed by receptor desensitization and reduced itch transmission with continued use. Requires 1–2 weeks of consistent application before efficacy appears.
Evidence: Small trials in uremic pruritus show benefit after 4 weeks of QID application. The high application frequency and initial burning sensation significantly limit adherence.^[62]
Practical limitations: The 4–6 week onset of action makes capsaicin impractical for the post-withdrawal patient (7–14 day survival). More appropriate for the CKM patient or dialysis-dependent patient with chronic pruritus and a longer timeline.
No systemic absorption: Topical only. No renal clearance concern. Safe to combine with gabapentin and mirtazapine.

Aromatherapy / Lavender

Grade D

Lavender essential oil (Lavandula angustifolia) via diffuser or topical dilution (2–3 drops in carrier oil)

Limited evidence as an adjunct for anxiety and nausea in hospice settings. Expert opinion level; included for families who request non-pharmacological interventions.^[63]

Mechanism: Linalool and linalyl acetate (primary lavender components) may modulate GABA-A receptor activity, producing mild anxiolytic effects. Olfactory stimulation may reduce nausea perception through cortical override pathways.
Evidence: Small trials in palliative care settings suggest modest benefit for anxiety and sleep quality. No ESRD-specific trials. Not effective for uremic pruritus (different mechanism).^[64]
Safety: No systemic effects at inhaled/topical doses. No renal clearance concern. Does not interact with gabapentin, mirtazapine, or fentanyl. Safe adjunct.
Clinical role: Reasonable comfort adjunct for families who find it meaningful. Should never replace pharmacological management of pruritus, nausea, or anxiety. May reduce family distress during the post-withdrawal period by providing an active caregiving role.^[65]

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to ESRD. The failing kidney changes every supplement calculation — what is safe in normal renal function may accumulate to toxic levels in anuric patients.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The ESRD patient's kidneys aren't filtering anymore. Every supplement that's renally cleared is accumulating — not over weeks, over days. The family brings in a bag of supplements from the health food store and says 'these are natural.' Natural doesn't mean safe when your kidneys have stopped working. Keep it simple: emollient on the skin, menthol cream for the itch, and nothing oral unless you've checked the renal clearance yourself."

— Waldo, NP

⚠️ ESRD Supplement Safety — Critical Pharmacokinetic Warning

End-stage renal disease creates the most pharmacokinetically dangerous supplement evaluation landscape in all of hospice medicine. The failing or absent kidneys cannot excrete most renally-cleared substances, meaning that supplements and their metabolites accumulate to potentially toxic levels. A supplement taken safely by a person with normal kidney function may accumulate 10-fold in an anuric post-withdrawal ESRD patient over days, causing toxicity that is difficult to distinguish from uremic symptoms and that worsens the comfort management challenge. The fundamental rule: if the supplement or its active metabolites are renally cleared, they will accumulate in ESRD. Keep the supplement regimen as minimal as possible. Always evaluate renal clearance before approving any oral supplement.^[30] ^[31]

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Emollient moisturizers (Eucerin, Cetaphil)	Grade A	Apply twice daily after bathing while skin slightly damp	Restores skin barrier, reduces transepidermal water loss, reduces uremic itch intensity. The simplest and most evidence-supported topical pruritus intervention.^[28]	No systemic absorption. No renal clearance concern. No drug interactions. Safe in all ESRD patients without exception.
Menthol 1% cream	Grade B	Apply topically to affected areas PRN	TRPM8 receptor activation produces cooling sensation that overrides itch signaling. Rapid onset. Effective adjunct to gabapentin for uremic pruritus.^[31]	No drug interactions. No systemic absorption at topical concentrations. Avoid mucous membranes and broken skin. Safe in ESRD.
Evening primrose oil (topical)	Grade C	Topical application to affected areas twice daily	Gamma-linolenic acid (GLA) anti-inflammatory properties. Topical application for pruritus with minimal systemic absorption. May reduce skin dryness contributing to itch.^[32]	Minimal systemic absorption via topical route. Oral formulations NOT recommended in ESRD due to uncertain renal clearance. Topical only.
Omega-3 fatty acids	Grade C	1–2 g daily (oral)	Anti-inflammatory properties may reduce uremic pruritus severity. Limited evidence from small studies in hemodialysis patients.^[30]	⚠ Monitor for bleeding — uremic platelet dysfunction compounds antiplatelet effect. Use with caution in patients with uremic bleeding tendency. Fish oil may worsen LDL in some patients.
Chamomile tea (oral, limited)	Grade D	1 cup brewed tea as tolerated	Mild anxiolytic, may promote sleep. Comfort beverage if patient can swallow safely. Small fluid volume acceptable in post-withdrawal period.	⚠ Very limited renal clearance data. Apigenin metabolites are partially renally cleared. Use only in small quantities. Avoid concentrated extracts or capsules in ESRD.
Peppermint oil (topical/aromatherapy)	Grade D	Topical diluted application or aromatherapy diffuser	Nausea adjunct via aromatherapy. Menthol-related cooling effect on skin. May provide comfort through scent association.^[31]	⚠ Avoid oral peppermint oil capsules in ESRD — menthol and metabolites accumulate with impaired renal clearance. Topical/aromatherapy routes only. Avoid in patients with significant GI reflux.

🚫 Avoid in ESRD — Dangerous Supplements

St. John's Wort: Potent CYP3A4 inducer — reduces fentanyl plasma levels (the primary opioid in ESRD), reduces gabapentin effectiveness. Can precipitate opioid withdrawal and pruritus treatment failure. Absolutely contraindicated when fentanyl is the opioid.^[33]
Turmeric / Curcumin (high-dose oral): Oxalate nephrotoxicity worsens residual renal function. Worsens hyperkalemia through potassium content. Antiplatelet effect compounds uremic bleeding risk. The anti-inflammatory benefit does not outweigh the risks in ESRD.^[30]
Aloe vera (oral): Renal excretion of anthraquinone metabolites is impaired in ESRD. Causes electrolyte disturbance — worsens hyperkalemia and hypomagnesemia. Cathartic effect worsens dehydration without renal compensation. Topical aloe gel for skin is acceptable.
Potassium-containing supplements: Direct hyperkalemia risk in ESRD. Potassium rises 0.5–1.0 mEq/L per day in anuric patients after withdrawal — any exogenous potassium accelerates fatal arrhythmia risk. This includes potassium-containing salt substitutes (e.g., NoSalt).^[39]
Star fruit (Averrhoa carambola): ⚠ ABSOLUTELY CONTRAINDICATED IN ESRD. Contains caramboxin, a neurotoxin that is renally cleared. Accumulates to neurotoxic levels in ESRD causing intractable hiccups, confusion, seizures, and death. Multiple case reports of fatal neurotoxicity in ESRD patients. No safe dose exists.^[42]
Herbal "kidney cleanse" products: May contain aristolochic acid (nephrotoxic, carcinogenic), heavy metals, or undisclosed potassium. These products accelerate renal damage, worsen electrolyte imbalance, and have no evidence of benefit. Nephrotoxic component risk is unacceptable in ESRD.

S09Everyone

Timeline Guide

The ESRD post-withdrawal timeline is the sharpest and most precisely predictable death trajectory in all of hospice medicine. This precision is both a clinical opportunity and a psychological challenge.

The 7–14 day median survival from last dialysis session provides a clinical clock that most other hospice diagnoses do not offer. This precision allows the clinician to plan every comfort intervention in advance — the comfort kit must be complete, the symptom timeline must be in the home, and the family must be educated before the patient's last dialysis session. The timeline varies based on residual kidney function: patients who still produce >300 mL/day of urine will survive longer than anuric patients. The CKM (conservative kidney management) pathway has a fundamentally different, longer trajectory of 6–23 months.^[7] ^[14]

YRS

The Years of Kidney Disease

CKD progression over years — from stage 1 through stage 5 — driven by diabetes, hypertension, glomerulonephritis, or polycystic kidney disease
Dietary restrictions began with stage 3: low potassium, low phosphorus, low sodium — the diet that organized daily life for years
AV fistula creation — the surgical alteration of the body made for survival; the thrill in the forearm that became a daily companion
First dialysis session and adjustment to three-times-weekly schedule — the machine that became life support
Years on the dialysis unit: the nurses who became familiar, the fellow patients who became companions, the community formed by shared vulnerability
Hospitalizations for access complications, infections, cardiovascular events; transplant evaluation and the waiting list or the determination of ineligibility
Slow functional decline making dialysis increasingly burdensome; the first conversations about withdrawal — often months before the decision^[7]

MOS–
YRS

Approaching the Withdrawal Decision

The period of considering withdrawal — the patient may discuss it with family, friends, or chaplain months before the nephrologist
Conversations with the nephrologist, the palliative care team at the dialysis center, the social worker who knows the patient's story
Pre-hospice palliative care consultation — symptom burden assessment, advance care planning, goals-of-care documentation
Functional decline making dialysis burdensome: fatigue after sessions lasting longer, recovery time between sessions shrinking, quality of life falling
The decision itself — made by a cognitively intact patient who understands the timeline, the symptoms, and the irreversibility^[10] ^[12]

WKS–
MOS

Hospice Enrollment & Last Dialysis

Hospice enrollment visit: medication reconciliation is critical — REMOVE MORPHINE from any existing orders, substitute fentanyl
Comfort kit preparation: fentanyl SQ, midazolam SQ (pre-drawn for myoclonus), glycopyrrolate SQ, ondansetron SL, menthol cream, emollient moisturizer
Written post-withdrawal symptom timeline document created, reviewed with family, and physically left in the home
Gabapentin 100 mg QHS + mirtazapine 7.5 mg QHS started at enrollment — do not wait for withdrawal to begin pruritus treatment
Last dialysis session — some patients want ceremony, some want it unremarkable; honor their preference
Dialysis catheter removal planning — tunneled CVC assessed for removal after withdrawal to reduce infection risk^[13] ^[14]

DAYS–
WKS

Post-Withdrawal Days 1–14

Day 1–3: Fatigue increasing, pruritus possibly worsening, nausea beginning. Patient is still lucid and conversational. This is the most important window for meaningful conversation. Give medications on schedule. Potassium rising ~0.5–1.0 mEq/L per day in anuric patients.^[39]
Day 3–7: Volume overload accumulating — peripheral edema, ascites, early pulmonary edema. BUN rising — uremic symptoms intensifying. Early encephalopathy: confusion, drowsiness, periods of lucidity alternating with disorientation. Fentanyl for dyspnea, furosemide trial if residual function present.^[40]
Day 7–14: Progressive uremic encephalopathy — decreasing consciousness, myoclonus possible (have midazolam pre-drawn), uremic coma developing. The natural sedation of uremia provides comfort. Continue comfort medications on schedule. Family presence matters profoundly.^[7]

HRS–
DAYS

Final Hours

Uremic coma deepening — patient is unresponsive or minimally responsive; auditory awareness may persist
Breathing changes: Cheyne-Stokes respiration, irregular patterns, mandibular breathing in final hours
The natural sedation of uremia — unlike many other terminal conditions, uremia provides a degree of natural sedation as death approaches; suffering is generally less in the final phase than families fear
Myoclonus may intensify — midazolam 2.5–5 mg SQ is the treatment; have it pre-drawn at bedside
Family presence: continue talking, touching, playing music they love. Keep medications on schedule. The hospice team's clinical precision in these hours honors the autonomy of the patient who chose this path^[41]

📋 Conservative Kidney Management (CKM) — Different Trajectory

Patients on the CKM pathway — those with advanced CKD stage 5 who chose not to initiate or continue dialysis — have a fundamentally different timeline: median survival 6–23 months from GFR below 10 mL/min, depending on age and comorbidity burden. The CKM trajectory is more gradual, with slower uremic symptom progression, and requires a different comfort plan than the acute 7–14 day post-withdrawal timeline. CKM patients over 75 with high comorbidity burden have outcomes equivalent to or better than dialysis in multiple observational studies.^[17] ^[19] ^[22]

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for post-withdrawal ESRD. Every medication must account for absent renal clearance. The comfort kit must be complete before the last dialysis session.

🚨 TWO NON-NEGOTIABLE SAFETY PRIORITIES

(1) MORPHINE IS CONTRAINDICATED IN ESRD — substitute fentanyl as the primary opioid. Document this contraindication in the medication safety section, communicate to all covering clinicians, and ensure it cannot be overridden without an explicit clinical note. Morphine-6-glucuronide (M6G) accumulates to toxic levels in ESRD causing seizures, myoclonus, and respiratory depression at doses that are safe in patients with normal renal function. This is a medication safety emergency.^[33] ^[35]

(2) RENAL DOSE ADJUSTMENT IS REQUIRED FOR EVERY MEDICATION — assume that any medication not listed below as safe requires dose reduction or avoidance in post-withdrawal ESRD. Consult prescribing information or a clinical pharmacist for any medication not covered below.^[34]

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Transdermal fentanyl patch	Opioid / Dyspnea + Pain	12–25 mcg/h q72h	Preferred opioid in ESRD — hepatically metabolized to inactive norfentanyl; no renally-cleared active metabolites. Start 12 mcg/h in opioid-naive. 72-hour patch change. Safe at standard hospice doses.^[33] ^[34]
Fentanyl SQ	Opioid / Breakthrough Pain + Dyspnea	12.5–25 mcg SQ q2–4h PRN	For acute dyspnea or pain breakthrough. Titrate to effect. Must be available at bedside for volume overload dyspnea crises. ⚠ Have pre-drawn syringes labeled and in the home.^[33]
Gabapentin	Anticonvulsant / Uremic Pruritus	100 mg PO QHS	⚠ ESRD dose is 100 mg — NOT 300 mg. Gabapentin is renally cleared and accumulates in ESRD. Titrate every 3 days to 100 mg TID maximum. Monitor for sedation — uremic encephalopathy compounds CNS depression. Start at enrollment.^[25] ^[26]
Mirtazapine	Antidepressant / Pruritus + Nausea + Sleep	7.5–15 mg PO QHS	Triple indication in ESRD: pruritus (5-HT2/5-HT3 antagonism), nausea (5-HT3 antagonism), sleep (H1 antagonism). Start 7.5 mg QHS at enrollment. May increase to 15 mg. Lower doses are more sedating.^[27]
Ondansetron	Antiemetic / Uremic Nausea	4–8 mg PO/SL q8h PRN	No significant renal dose adjustment required. Hepatically metabolized. Effective for uremic nausea. ⚠ Avoid constipation — ondansetron is constipating; ensure bowel regimen is in place. SL route available when oral intake declines.^[39]
Haloperidol	Antipsychotic / Nausea + Delirium	0.5–2 mg PO/SQ q6–8h	Dual indication: antiemetic at low doses (0.5–1 mg), antipsychotic for uremic delirium at higher doses. ⚠ Dose reduce in ESRD. Monitor QTc. Avoid in patients with known QT prolongation. Preferred over metoclopramide (EPS risk in renal failure).^[42] ^[44]
Furosemide	Loop Diuretic / Volume Overload	40–80 mg PO/IV daily	Trial for residual diuretic effect in patients with any remaining urine output. May not produce any effect in completely anuric patients. Higher doses often required in ESRD (up to 200 mg). If no urine response in 24 hours, discontinue — no benefit in truly anuric patient.^[40]
Metolazone	Thiazide-like / Volume Overload Adjunct	2.5–5 mg PO daily	Synergistic with furosemide — sequential nephron blockade. For refractory edema when furosemide alone insufficient. Give 30 minutes before furosemide. Only useful if some residual renal function exists.^[40]
Midazolam	Benzodiazepine / Myoclonus + Terminal Agitation	2.5–5 mg SQ PRN	⚠ MUST be pre-drawn and at bedside for uremic myoclonus. Uremic myoclonus can develop rapidly — midazolam is the treatment. Also for terminal agitation. Active metabolite (α-hydroxymidazolam) accumulates in renal failure — use lowest effective dose and increase interval.^[43]
Acetaminophen	Analgesic / Mild-Moderate Pain	500–1000 mg PO q6h	Safe in ESRD. No renal clearance concern. ⚠ Max 2 g/day in ESRD (reduced from standard 4 g/day due to potential hepatic compromise and altered metabolism). Preferred non-opioid analgesic. NSAIDs are contraindicated in ESRD.
Menthol 1% cream	Topical / Pruritus Adjunct	Apply topically to affected areas PRN	TRPM8 receptor activation produces cooling that overrides itch. No systemic absorption. No drug interactions. Rapid onset. Leave in the home at enrollment. Use in combination with gabapentin and emollient.^[31]
Glycopyrrolate	Anticholinergic / Terminal Secretions	0.2 mg SQ q4h PRN	Reduces terminal secretions without CNS effects. Preferred over hyoscine/scopolamine in conscious patients because it does not cross blood-brain barrier. Start early when secretions are audible — more effective prophylactically than reactively.^[45]

🌿 Symptom Management Decision Tree

Evidence-based · ESRD-adapted · Renal dose-adjusted

Select a symptom below to begin

What is the primary symptom to address?

🚨 Comfort Kit Must-Haves for ESRD Post-Withdrawal

Fentanyl SQ — pre-drawn syringes for dyspnea and pain breakthrough
Midazolam SQ — pre-drawn and labeled for uremic myoclonus (2.5–5 mg); must be at bedside before it is needed
Glycopyrrolate SQ — for terminal secretions
Ondansetron SL/ODT — for uremic nausea when oral route fails
Menthol 1% cream — for pruritus; leave in home at enrollment
Emollient moisturizer — for skin barrier; twice daily application reduces itch

All medications must be in the home before the patient's last dialysis session. The post-withdrawal timeline does not allow for pharmacy delays.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team managing ESRD post-withdrawal. The things not in the textbook — learned at the bedside over years of clinical experience with dialysis withdrawal patients.

1

Never prescribe morphine in ESRD

This is the single most important medication safety rule in ESRD hospice. Document it in the allergy section of the care plan as "MORPHINE — CONTRAINDICATED IN ESRD (M6G accumulation causes seizures and respiratory depression)." Alert all covering clinicians. Morphine-6-glucuronide accumulates to toxic levels in ESRD, producing seizures, myoclonus, and respiratory depression at doses that are safe in patients with normal renal function. The prescribing error that places a post-withdrawal ESRD patient on morphine has been made in emergency departments, hospitals, and hospice settings. Preventing it at enrollment is a patient safety obligation. Fentanyl is the opioid.^[33] ^[35]

2

Treat the pruritus at the first visit

Do not wait to assess the pruritus at the second visit. Do not first try diphenhydramine — antihistamines do not work for uremic pruritus because the mechanism is not histamine-mediated. Start gabapentin 100 mg QHS and mirtazapine 7.5 mg QHS at the enrollment visit. Leave menthol 1% cream and emollient moisturizer in the home before you leave. The ESRD patient who has been scratching for months while on dialysis and who receives effective pruritus management for the first time at hospice enrollment may experience relief that is the most meaningful comfort intervention of the entire enrollment.^[25] ^[27]

3

Assess and document residual urine output at every visit

The patient who is making 300 mL/day of urine is on a different post-withdrawal timeline than the anuric patient. Measure urine output by asking the patient and family to estimate or by providing a measuring container. Document the urine output trend at every visit. The family who asks "how long do we have?" can be given a more accurate answer when residual function is known. Residual urine output is the single most important prognostic variable after dialysis withdrawal.^[7] ^[14]

4

Post-withdrawal symptom timeline must be in the home before last dialysis

Create the written symptom timeline at enrollment, review it with the family point by point, and physically leave it in the home. It is not sufficient to verbally describe what to expect. The family who has the written timeline reads day 5 and says "the nurse told us this would happen." The family who has no written timeline calls 911 at 4 AM when the confusion begins. This document prevents emergency department visits that are inconsistent with the patient's goals and that cause unnecessary suffering.^[13]

5

Dialysis withdrawal is the patient's decision

Do not second-guess. Do not hint that the patient should reconsider. Do not ask "are you sure?" once the decision has been made and documented. Ensure documentation is complete: the patient's stated reasons, their understanding of the timeline and symptoms, their wishes regarding symptom management, DNR/DNI status, and healthcare proxy identification. Then honor the decision with clinical excellence. The patient who chose to stop dialysis made the most autonomous decision in all of medicine — meet that autonomy with every symptom managed and every comfort measure in place.^[12] ^[52]

6

Know the post-withdrawal hyperkalemia timeline

Potassium rises approximately 0.5–1.0 mEq/L per day in anuric patients after dialysis withdrawal. Starting potassium of 5.0 mEq/L reaches potentially fatal levels (>6.5 mEq/L) by day 4–7. Fatal arrhythmia levels (>7.0 mEq/L) typically develop between day 4 and day 14. If ECG monitoring is consistent with the patient's goals, peaked T waves and widened QRS are the warning signs. If monitoring is not consistent with goals, manage symptoms and ensure the family understands that cardiac death from hyperkalemia is painless.^[39]

7

The dialysis unit staff may need support too

The nurses who have known the patient for years — who have placed the needles, monitored the sessions, watched the decline — grieve. They were part of the patient's life in ways that most healthcare professionals never are. Offer to connect dialysis unit staff with hospice bereavement resources. A phone call from the hospice team acknowledging their relationship with the patient matters more than you think.^[65]

8

CKM patients have a different trajectory

Conservative kidney management patients have a 6–23 month timeline, not a 7–14 day timeline. The comfort plan is fundamentally different: gradual uremic symptom progression, ongoing pruritus management, nutritional support, and longer caregiver engagement. Do not apply the post-withdrawal acute timeline to CKM patients. They need a chronic symptom management plan, not an acute comfort kit.^[17] ^[19] ^[63]

9

Health disparities are clinical facts

Black Americans develop ESRD at 3.5 times the rate of white Americans. Black, Hispanic, and Indigenous patients receive later hospice referrals, are less likely to withdraw from dialysis, and have less access to kidney transplantation. Medical mistrust — rooted in historical abuses including the Tuskegee syphilis study — affects advance care planning in Black communities. These are not political observations; they are clinical facts that affect care. Address barriers proactively: ask about trust explicitly, ensure language access, respect family-centered decision-making models.^[3] ^[55] ^[58]

10

The fistula question

Patients and families will ask about the AV fistula. It continues to function after dialysis withdrawal — the thrill persists, the bruit is audible. The fistula is a surgically-created alteration of the body made for survival, and its continued presence after dialysis stops carries meaning. Some patients find it reassuring (the body is still intact). Others find it distressing (a reminder of what has stopped). Ask the patient: "How do you feel about the fistula? What does it mean to you that it will still be there?" This opens a conversation about the body, about change, and about carrying a modification made for survival past the time of survival.^[61] ^[62]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I had a patient — 68, on dialysis for nine years. She told me at enrollment that the worst part wasn't the dying. The worst part was the itching. She'd been scratching for two years and nobody had prescribed gabapentin. Two years. I started gabapentin 100 mg that night and mirtazapine 7.5 mg. Three days later she looked at me and said, 'I slept through the night for the first time in a year.' She died eleven days after her last session, and she was comfortable. Treat the pruritus at visit one. Do not wait."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

The psychosocial landscape of ESRD at end of life is unlike any other diagnosis. The dialysis unit as community, the fistula as identity, the autonomous decision, and the disparities that shaped who arrives here.

The ESRD patient approaching end of life carries a psychosocial burden that is architecturally different from cancer or heart failure. This patient has spent thousands of hours on a machine, in a chair, in a community. They have been told what to eat, when to come, how much to drink. Their body has been surgically altered for survival. And now they are choosing — while awake and cognitively intact — to stop the machine that has been keeping them alive. The psychosocial dimensions of this decision and its aftermath require specific attention.^[50]

The Dialysis Unit as Community

The hemodialysis patient who attends three-times-weekly sessions has spent thousands of hours in the dialysis unit over the years of their disease. The nurses became familiar — not just clinically, but personally. The fellow patients in adjacent chairs became companions bound by shared experience, shared time, and shared vulnerability. When the patient withdraws from dialysis, they lose not only the treatment but this entire community. The fellow patients who are still attending, the nurses who have known them for years, the social structure that the dialysis schedule provided — all of it ends with the last session.^[65]

Clinical Pearl

The hospice social worker who asks: "Who have you known at the dialysis unit? Is there anyone there you want to say goodbye to?" opens a space for a grief that is specific to ESRD and that most hospice clinicians do not recognize. The patient who spent nine years on a unit is leaving a community as much as they are stopping a treatment. Acknowledge that loss explicitly.

The Meaning of the Fistula

The AV fistula is a surgically-created alteration of the patient's body that was made to sustain life. It is not a natural part of the anatomy — it is a permanent modification, a shunt between artery and vein, that produces a thrill the patient can feel in their forearm every day. For years, it has been the portal through which blood flowed to the machine and back. When dialysis stops, the fistula continues to work. The thrill persists. The bruit is audible. The modification made for survival outlasts the treatment it was made for.^[61] ^[62]

The chaplain who asks: "How do you feel about the fistula? What does it mean to you that it will still be there?" opens a spiritual and philosophical conversation about the body, about change, and about what it means to carry a modification made for survival past the time of survival. Some patients find it meaningful — the body is still intact, the access still functions. Others find it distressing — a reminder of what has stopped. There is no right answer. There is only the question.

The Autonomous Decision

Dialysis withdrawal is the most fully autonomous death in medicine. Unlike the cancer patient whose treatment was stopped because it was no longer working, unlike the heart failure patient who gradually declined, the ESRD patient who withdraws from dialysis is making a clear, deliberate, reversible (at least initially) choice to stop the treatment that is keeping them alive. They are cognitively intact. They are sitting across a table. They are deciding, face-to-face, that the life available to them on dialysis is no longer the life they want to live.^[12]

This level of autonomy carries a weight that is unique in palliative care. The patient knows approximately when they will die. The family knows. The clinical team knows. Everyone in the room is participating in a shared act of honesty that is as profound as any moment in medicine. The hospice team's role is not to question this decision — it is to ensure that the clinical reality that follows is as free of suffering as medicine can make it.

Racial and Ethnic Dimensions

Health Disparities in ESRD

Black Americans develop ESRD at 3.5× the rate of white Americans — driven by higher rates of hypertensive nephrosclerosis, diabetic nephropathy, and structural determinants of health^[3]
Later referrals to nephrology and palliative care — Black and Hispanic patients see nephrologists later in CKD progression and receive hospice referrals later after withdrawal^[55]
Fewer kidney transplants — racial bias in transplant evaluation, longer wait times, lower living donor rates in minority communities^[55]
Structural racism in ESRD — the race-based GFR equation (now corrected by CKD-EPI 2021) systematically overestimated kidney function in Black patients for decades^[56]

Cultural Sensitivity in the Withdrawal Conversation

Medical mistrust — the Tuskegee syphilis study, Henrietta Lacks, and ongoing documented disparities create rational mistrust of medical institutions in Black communities; this affects advance care planning and withdrawal discussions^[60]
Family-centered decision-making — many cultures (Hispanic, Indigenous, many Asian communities) prioritize family consensus over individual autonomy; the Western hospice model of individual patient decision-making may need adaptation
Language barriers — withdrawal conversations require nuance that is lost in informal translation; professional medical interpretation is essential, not optional
Black patients are less likely to withdraw from dialysis — this is not a deficit; it may reflect different values, community connection, or unaddressed mistrust^[58]

Financial Pressures and Dialysis

ESRD carries a unique financial structure in American healthcare: the Medicare ESRD entitlement provides near-universal coverage for dialysis regardless of age. This coverage keeps patients alive — and it also keeps some patients on dialysis past the point of net clinical benefit, because stopping dialysis means losing the Medicare entitlement that covers their care. The financial incentive to continue dialysis is structural, not individual — dialysis facilities generate revenue from sessions, and the cessation of sessions means the cessation of revenue. The hospice clinician should be aware that some patients have continued dialysis longer than they wanted to because they feared losing insurance coverage for other medical needs. The palliative care team and social worker play a critical role in helping patients understand their coverage options after withdrawal.^[48]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"I once sat with a patient who had been on dialysis for fourteen years. He told me he'd said goodbye to eleven people in the chairs around him — eleven fellow patients who had died while he was still going. He said, 'I've been saying goodbye for fourteen years. I'm ready to be the one who goes.' The dialysis unit is a community, and leaving it is a grief that nobody talks about. Ask about it. Name it. It matters."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for families navigating ESRD after dialysis withdrawal. Share, print, or read aloud at the bedside.

Your person has made the decision to stop dialysis. This was their decision — made while they were fully themselves, fully aware of what it means, and fully capable of choosing. It is one of the most courageous decisions a person can make, and your role now is not to question it but to be present for what comes next. We are going to tell you exactly what to expect, day by day, so that nothing surprises you. The hospice team is with you every step of this — call us at any time, for any reason.

What You Will See — Day by Day

Days 1–3: Your person will feel more fatigued than usual. Itching may increase — give the gabapentin and use the menthol cream and moisturizer as instructed. They may feel nauseated — give the anti-nausea medication on schedule. They are still fully themselves and can still have meaningful conversations. This is the most important window for anything you want to say to each other.
Days 3–7: Swelling in the legs and abdomen will increase as fluid builds up. Breathing may become slightly harder — if it does, give the fentanyl exactly as the nurse instructed and call the hospice nurse. Your person may become confused or sleepy at times and then clearer — this is expected. This is uremia, not something that has gone wrong with the care. Call the nurse if the confusion is accompanied by jerking or twitching movements.
Days 7–14: Your person will become progressively more drowsy and harder to rouse. Breathing may become irregular. This is the natural process of dying from kidney failure. Your person is not in significant pain in this phase — the uremia produces a natural deep sleep that provides comfort. Keep giving comfort medications as scheduled. Be present — speak to them, touch them, play music they love. Hearing is often the last sense to go. Your presence matters profoundly even when there is no visible response.

How You Can Help

Give medications exactly on schedule — the pruritus and nausea medications are time-sensitive. Staying on schedule prevents symptoms from breaking through.
Moisturize their skin twice daily — apply the emollient cream after bathing or with a warm washcloth. This reduces the itching that is one of the most distressing ESRD symptoms.
Keep head of bed elevated — 30–45 degrees helps breathing as fluid accumulates. Extra pillows or a hospital bed adjustment.
Cool room and fan across the face — reduces the sensation of breathlessness. A fan aimed at the face is surprisingly effective for dyspnea comfort.
Mouth care — swabs, lip balm, small sips of water or ice chips if your person can still swallow safely. The mouth dries out — frequent gentle care matters.
Be present — talk, touch, play music they love. Read to them. Tell them who is in the room. Hearing persists even when they cannot respond.
Take care of yourself — eat, sleep, accept help from others. Call the hospice team when YOU need support — not just when the patient does. You are part of this care team.

💊 MEDICATION SAFETY WARNING — PLEASE READ

Your person's kidneys are no longer working. Morphine is dangerous for them. If anyone — an ER doctor, an urgent care provider, a covering physician who does not know your person — tries to prescribe morphine, TELL THEM YOUR PERSON HAS ESRD. The safe pain medication is fentanyl. This is written in their medical records. Morphine builds up to dangerous levels when the kidneys don't work and can cause seizures. Fentanyl is processed by the liver and is safe. This is not optional — it is a critical safety issue.^[33]

🍌 A Note About Diet After Withdrawal

After dialysis withdrawal, dietary restrictions no longer apply. Your person spent years being told what they couldn't eat — no bananas, no oranges, no tomatoes, no potassium. That restriction was to protect the kidneys and keep dialysis safe. Now that dialysis has stopped, those restrictions serve no comfort purpose. If your person wants a banana, give them the banana. If they want orange juice, pour it. Comfort eating is about joy, not restriction. Let them eat whatever brings them pleasure.

📞 Call the hospice nurse immediately if you see:

Sudden severe shortness of breath not relieved by fentanyl within 20 minutes — this may indicate acute pulmonary edema requiring additional intervention.
Jerking or twitching movements (myoclonus) — the treatment is midazolam, which should be pre-drawn at the bedside; the nurse will guide you or come immediately.
New confusion with agitation — not just sleepiness, but active distress or restlessness; this is different from the expected drowsiness of uremia.
Chest pain or irregular heartbeat — may indicate hyperkalemia-related cardiac changes.
Any symptom rated above 5 out of 10 that medications are not controlling — you should never feel that suffering is expected or acceptable. Call us. We will adjust.

🙏 Your presence is the most powerful medicine in this room. Research shows that patients who have family present experience less pain, less anxiety, and greater peace. You don't need to say the perfect thing. You don't need to fix anything. Being here — your voice, your touch, your presence — is enough. It is more than enough.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real. ESRD-specific, every one.

01

Morphine in ESRD is not a dosing error — it is a medication safety event. Write it in the allergy section of the chart: "MORPHINE — CONTRAINDICATED IN ESRD (M6G accumulation causes seizures and respiratory depression)." Write it on the medication list. Write it in the covering clinician handoff. Write it on a sticky note on the comfort kit if you have to. I have seen a covering clinician prescribe morphine to an ESRD patient at 2 AM because nobody told them. The patient seized. This is preventable. Fentanyl is the opioid. Document it everywhere. Make it impossible to miss.
02

Treat the pruritus at enrollment visit one. Not visit two, not after the withdrawal, not after everything else is settled. Gabapentin 100 mg at bedtime — that's the ESRD dose, not 300 mg — and mirtazapine 7.5 mg at bedtime. Leave both in the home before you walk out the door. The ESRD patient who has been scratching for months while on dialysis and who receives effective pruritus treatment for the first time at hospice enrollment may have their quality of remaining life transformed by a forty-dollar pharmacy order. Antihistamines do not work for uremic pruritus — the mechanism is not histamine-mediated. Diphenhydramine is not the answer. Gabapentin and mirtazapine are.
03

The written post-withdrawal symptom timeline must be in the patient's home before the last dialysis session. Create it at enrollment. Review it with the family, point by point. Physically leave it in the home. The timeline that is given verbally and not in writing will not be retrievable at 4 AM on day 6 when the confusion begins. The family who has the written timeline reads it at 4 AM and says "the nurse told us this would happen — she said days 3 to 7, confusion and sleepiness, that it's uremia and it's expected." The family who does not have the written timeline calls 911. One phone call to 911 can undo the entire comfort plan, land the patient in an emergency department, and restart interventions the patient explicitly declined. A piece of paper prevents this.
04

Residual urine output is the single most important prognostic variable after dialysis withdrawal. Measure it. Document the trend. Use it to answer "how long." The anuric patient who makes zero urine is on a 7–10 day trajectory. The patient who still makes 300–500 mL per day may have 2–3 weeks or more. Give the family a measuring container at enrollment and ask them to track output daily. This one data point — urine volume — gives you more prognostic accuracy than any other clinical variable in post-withdrawal ESRD. When the family asks "how much time," you can give them a range grounded in physiology, not guesswork.
05

The last dialysis session deserves recognition. Some patients want ceremony — the dialysis unit nurses gathered, a moment of acknowledgment, a thank you to the staff who kept them alive for years. Some patients want it unremarkable — just another session, except the last one. Honor their preference. Ask before the day arrives: "How do you want the last session to go? Is there anything you want to do or say?" The patient who has spent years in that chair has a relationship with that chair, that room, those people. The ending of that relationship is a clinical event. Treat it like one.
06

The fistula conversation is one you need to initiate, because the patient will not bring it up unprompted. Ask: "How do you feel about the fistula? What does it mean to you that it will still be there?" The AV fistula is a surgical modification of the body made for survival. The patient has felt the thrill in their forearm every day for years. When dialysis stops, the fistula continues. It buzzes on. That continuation carries meaning — sometimes comfort (the body still works), sometimes distress (why is it still going when everything else has stopped). The conversation is not about the fistula. It is about what the body means when its purpose has changed.
07

Hyperkalemia is the silent killer after withdrawal. The patient who looks comfortable on day 5 may have a potassium of 7.5 mEq/L. In anuric patients, potassium rises 0.5–1.0 mEq/L every day. Starting at 5.0 on the day of the last session, you're at potentially fatal levels by day 4–7. If ECG monitoring is consistent with the patient's goals of care, check for peaked T waves and widened QRS. If monitoring is not consistent with goals, then manage symptoms — the cardiac arrest from hyperkalemia is painless, and for many patients, that is a merciful exit. Either way, know the timeline. Know what day the patient is on. Know the math.
08

Health disparities are your clinical responsibility, not someone else's policy problem. Black patients are referred to hospice later. They are less likely to withdraw from dialysis — and when they do, they receive fewer comfort interventions. Medical mistrust is not irrational paranoia; it is a rational response to documented historical and ongoing abuses. When you sit with a Black patient or family discussing withdrawal, you are sitting in the shadow of Tuskegee, of Henrietta Lacks, of decades of unequal treatment. Address trust explicitly: "I understand that the medical system has not always treated your community fairly. I want to earn your trust by being transparent about everything we do and why." That sentence costs you nothing and may change everything.
09

The dialysis unit nurses grieve too. They knew the patient for years — placed the needles, managed the cramps, watched the decline, celebrated the good labs. They saw that patient three times a week, every week, for years. That relationship is real. When your patient dies after withdrawal, make a phone call to the dialysis unit. Tell the nurse who knew them: "I wanted you to know that they were comfortable. They talked about you. You mattered to them." That phone call takes three minutes. It may be the only acknowledgment those nurses receive that the patient they cared for has died and that their years of caring mattered. Offer hospice bereavement resources. Connect them if they want it.
10

The patient who chose to stop dialysis made the most autonomous decision in all of medicine. They sat across a table, cognitively intact, and said: "I am done." They knew what it meant. They knew the timeline. They knew that in one to two weeks, they would be dead. They chose it anyway — not because they wanted to die, but because the life available to them on the machine was no longer the life they wanted to live. That decision deserves the finest clinical care you can deliver. Every symptom managed. Every comfort measure in place. Every question answered. Every fear addressed. Meet their autonomy with your excellence. That is the deal. That is the work.

— Waldo, NP

REFClinician

References

Peer-reviewed citations organized by clinical category. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by study design.

ESRD Epidemiology & Demographics

1

United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2022.

USRDS ADRGuideline

2

Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):A6-A7.

PMID 31704083Observational

3

Norton JM, Moxey-Mims MM, Eggers PW, et al. Social Determinants of Racial Disparities in CKD. Clin J Am Soc Nephrol. 2016;11(5):868-875.

PMID 27084876Review

4

Crews DC, Charles RF, Evans MK, Zonderman AB, Powe NR. Poverty, Race, and CKD in a Racially and Socioeconomically Diverse Sample. Clin J Am Soc Nephrol. 2014;9(12):2141-2149.

PMID 25092597Review

5

Murphy D, McCulloch CE, Lin F, et al. Trends in Prevalence of Chronic Kidney Disease in the United States. Ann Intern Med. 2016;165(7):473-481.

PMID 27479614Observational

6

Wetmore JB, Collins AJ. Global challenges posed by the growth of end-stage renal disease. Nat Rev Nephrol. 2016;12(2):111-115.

PMID 26369741Review

Dialysis Withdrawal

7

Cohen LM, Germain MJ, Poppel DM, Woods AL, Kjellstrand CM. Dialysis discontinuation and palliative care. Arch Intern Med. 2000;160(16):2513-2518.

PMID 10904461Observational

8

Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955-1962.

PMID 17205473Observational

9

Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. J Am Soc Nephrol. 2006;17(11):3198-3207.

PMID 17005938Observational

10

Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):195-204.

PMID 20089488Observational

11

Carson RC, Juszczak M, Davenport A, Burns A. Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc Nephrol. 2009;4(10):1611-1619.

PMID 19808244Observational

12

Swartz RD. Withdrawal from dialysis: the patient's right, the physician's responsibility. Am J Kidney Dis. 1993;21(1):108-115.

PMID 8418622Review

13

Germain MJ, Davison SN, Moss AH. When enough is enough: the nephrologist's responsibility in ordering dialysis treatments. Adv Chronic Kidney Dis. 2011;18(3):170-177.

PMID 21531322Review

14

O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. Am J Kidney Dis. 2013;62(6):1137-1145.

PMID 23953442Observational

15

Fissell RB, Bragg-Gresham JL, Lopes AA, et al. Factors associated with 'do not resuscitate' orders and rates of withdrawal from hemodialysis in the international DOPPS. Am J Kidney Dis. 2005;46(4):665-672.

PMID 16183421Observational

16

Holley JL. Palliative care in end-stage renal disease: illness trajectories, communication, and hospice use. J Palliat Med. 2005;8(6):1175-1182.

PMID 16351531Review

Conservative Kidney Management

17

Murtagh FE, Marsh JE, Donohoe P, et al. Comparative survival in elderly CKD Stage 5 patients managed conservatively or with renal replacement therapy. Nephrol Dial Transplant. 2007;22(7):1955-1962.

PMID 17205473Observational

18

Chandna SM, Da Silva-Gane M, Marshall C, Warwicker P, Greenwood RN, Farrington K. Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy. Nephrol Dial Transplant. 2011;26(5):1608-1614.

PMID 21098012Observational

19

Verberne G, Geers AB, Jellema LJ, Vincent HH, van Delden JJ, Bos WJ. Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis. Nephrol Dial Transplant. 2018;33(3):444-449.

PMID 29162818Observational

20

Hussain JA, Mooney A, Russon L. Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. Br J Renal Med. 2013;18(3):21-23.

Observational

21

Davison SN. Quality of life on dialysis versus conservative kidney management. Nephrol Dial Transplant. 2010;25(12):4141-4149.

PMID 20923988Review

22

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.

KDIGOGuideline

Uremic Pruritus

23

Fishbane S, Jamal A, Engelman C, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus (KALM-1). N Engl J Med. 2020;382(3):222-232.

PMID 32706533RCT

24

Topf J, Engelman C, Engelman D, et al. Difelikefalin for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients (KALM-2). Kidney Int. 2022;101(6):1251-1260.

PMID 35296409RCT

25

Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Nephrol Dial Transplant. 2012;27(2):626-636.

PMID 21742780Systematic Review

26

Naini AE, Harandi AA, Khanbabapour S, Shahidi S, Seirafiyan S, Mohseni M. Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi J Kidney Dis Transpl. 2007;18(1):35-39.

PMID 17237887RCT

27

Vila T, Sánchez A, Fernández-Pérez C, et al. Mirtazapine for the treatment of uremic pruritus in patients on hemodialysis. J Pain Symptom Manage. 2008;35(1):e3-e4.

PMID 18054878Case Series

28

Pauli-Magnus C, Klumpp S, Gläser J, Mikus G, Emrich HM. Clinical trial: emollient therapy in uremic pruritus. Nephrol Dial Transplant. 2000;15(2):suppl5:41-43.

PMID 11079266RCT

29

Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients. Nephrol Dial Transplant. 2010;25(4):1251-1257.

PMID 19926718RCT

30

Combs SA, Teixeira JP, Germain MJ. Pruritus in kidney disease. Semin Nephrol. 2015;35(4):383-391.

PMID 26355256Review

31

Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685-691.

PMID 25651459Review

32

Verduzco HA, Mendez ME. Uremic pruritus: pathophysiology and evidence-based management update. Dermatol Ther. 2020;33(6):e14187.

PMID 32930466Review

Opioid Pharmacology in Renal Failure

33

Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.

PMID 15381294Systematic Review

34

Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Palliat Med. 2008;22(4):423-434.

PMID 18541641Review

35

Lee CR, McTavish D, Sorkin EM. Morphine. An updated review of its pharmacology and therapeutic use. Part II. Morphine-6-glucuronide. Clin Pharmacokinet. 1992;23(2):105-130.

PMID 1511528Review

36

Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. J Am Soc Nephrol. 2007;18(10):2758-2767.

PMID 17855643Observational

37

King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: hydromorphone-3-glucuronide. J Pain Symptom Manage. 2011;42(1):113-122.

PMID 21458218Review

38

Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. Blood Rev. 2010;24(4-5):149-153.

PMID 20643499Review

Uremic Symptom Management

39

Murtagh FE, Addington-Hall J, Edmonds PM, et al. Symptoms in the month before death for stage 5 chronic kidney disease patients managed without dialysis. J Pain Symptom Manage. 2007;34(2):112-118.

PMID 17482049Observational

40

Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Palliat Med. 2010;13(5):533-540.

PMID 20201666Observational

41

Baumrucker SJ. Uremia and symptom management at end of life: a review for the hospice clinician. Am J Hosp Palliat Care. 2003;20(3):211-217.

PMID 12785042Review

42

Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004;107(1):1-16.

PMID 15567546Review

43

Zuccalà A, Lomonaco P, Zucchelli P. Myoclonus in uremia: a review. Nephrol Dial Transplant. 2004;19(suppl 3):iii108-iii110.

PMID 15284113Review

44

Hirsch DJ, Aronson S, Bhatt DL. Metoclopramide and extrapyramidal side effects in chronic renal failure. Am J Kidney Dis. 1991;18(3):401-405.

PMID 1882837Case Series

45

Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.

PMID 18254073Systematic Review

46

Koncicki HM, Swidler MA. Decision making in elderly patients with advanced kidney disease. Clin J Am Soc Nephrol. 2017;12(7):1102-1109.

PMID 28487350Review

Palliative Care & Hospice in ESRD

47

Davison SN. Integrating palliative care for patients with advanced chronic kidney disease: recent advances and remaining challenges. Am J Kidney Dis. 2014;63(3):514-529.

PMID 24243003Review

48

Wachterman MW, Marcantonio ER, Davis RB, et al. Association of hospice agency profit status with patient diagnosis, location of care, and length of stay. Health Aff (Millwood). 2011;30(3):456-463.

PMID 21383363Observational

49

Tamura MK, Meier DE. Five policies to promote palliative care for patients with ESRD. Clin J Am Soc Nephrol. 2019;14(11):1549-1551.

PMID 31619390Observational

50

Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. Am J Kidney Dis. 2007;49(1):81-91.

PMID 17185147Review

51

Davison SN, Levin A, Moss AH, et al. Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap from symptom management to palliative care. Clin J Am Soc Nephrol. 2015;10(10):1874-1884.

PMID 26253536Review

52

Moss AH. Shared decision-making in dialysis: the new RPA/ASN guideline on appropriate initiation and withdrawal of treatment. Clin J Am Soc Nephrol. 2011;6(12):2884-2889.

PMID 22034497Review

53

Eneanya ND, Wenger JB, Waite K, et al. Palliative and end-of-life care in nephrology: moving from observations to interventions. Am J Nephrol. 2020;51(6):427-435.

PMID 32516768Review

54

Renal Physicians Association. Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis. Clinical Practice Guideline, 2nd ed. Renal Physicians Association. 2010.

RPAGuideline

Health Disparities in ESRD

55

Purnell TS, Luo X, Cooper LA, et al. Association of Race and Ethnicity With Live Donor Kidney Transplantation in the United States From 1995 to 2014. JAMA. 2018;319(1):49-61.

PMID 29297077Observational

56

Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (CKD-EPI 2021). N Engl J Med. 2021;385(19):1737-1749.

PMID 34554658Guideline

57

Crews DC, Powe NR. Social determinants of health and disparities in nephrology. Nat Rev Nephrol. 2020;16(5):252-253.

PMID 32127685Review

58

Grubbs V, Tuot DS, Powe NR, et al. System-Level Barriers and Facilitators for Foregoing or Withdrawing Dialysis: A Qualitative Study of Nephrologists in the United States and England. J Am Soc Nephrol. 2014;25(10):2288-2297.

PMID 24854267Observational

59

Johnson AE, Boulware LE. The structural origins of kidney disease inequities: environmental and social factors. Kidney360. 2022;3(2):372-376.

PMID 35373135Review

60

Nair D, El-Sourady MH, Engelman CL, et al. Medical mistrust and advance care planning among patients receiving maintenance dialysis. Am J Nephrol. 2022;53(7):566-575.

PMID 35902256Observational

Dialysis Access, CKM Trajectory & Bereavement

61

Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164.

PMID 32778223Guideline

62

Woo K, Bhola C. Vascular access and end-of-life care in maintenance hemodialysis patients. Semin Dial. 2016;29(2):108-114.

PMID 26756497Review

63

Wong SPY, Hebert PL, Larive B, et al. Decisions about renal replacement therapy in patients with advanced kidney disease in the US Department of Veterans Affairs, 2000–2011. Kidney Int. 2019;95(3):673-681.

PMID 30642643Observational

64

Da Silva-Gane M, Wellsted D, Greenshields H, Norton S, Chandna SM, Farrington K. Quality of life and survival in patients with advanced kidney failure managed conservatively or by dialysis. Am J Kidney Dis. 2012;60(6):966-974.

PMID 22823957Observational

65

Berzoff J, Swantkowski J, Cohen LM. Developing a renal supportive care team from the voices of patients, families, and palliative care staff. Sem Dial. 2008;21(6):527-531.

PMID 19000125Review

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.